Vinatier Hospital
Reality-monitoring characterizes the ability to determine whether information was perceived in the environment or only imagined . Impaired reality-monitoring abilities have been associated with hallucinations in patients with schizophrenia and patients with Parkinson's disease. The investigators hypothesize a link between dopaminergic (DA) transmission and reality-monitoring.
Neurosciences
Dopamine precursor
Production listened
PLACEBO
Not Applicable
This hypothesis is based on several studies in the literature: 1) DA transmission anomalies are observed in both schizophrenia and Parkinson's disease; 2) DA agonists may induce hallucination; 3) DA antagonists reduce hallucinations and improve reality-monitoring abilities in patients with schizophrenia. In addition, also suggesting a link between mesocorticolimbic connectivity, subcortical DA transmission and reality-monitoring, The investigators have shown that fronto-temporal transcranial Direct Current Stimulation (tDCS) leads: on the one hand, to modulate reality-monitoring performance in healthy volunteers and patients; on the other hand, to induce subcortical DA release. However, to date, no study has yet explored the direct link between DA transmission and reality-monitoring.}}
| Study Type : | Interventional |
| Estimated Enrollment : | 39 participants |
| Masking : | Single |
| Masking Description : | double dummy, placebo-controlled |
| Primary Purpose : | Basic Science |
| Official Title : | MONITORING OF REALITY AND DOPAMINE: A PHARMACOLOGICAL RESEARCH |
| Actual Study Start Date : | January 15, 2024 |
| Estimated Primary Completion Date : | June 30, 2026 |
| Estimated Study Completion Date : | December 31, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Dopamine precursor In the first condition, volunteers will receive a dopamine (DA) precursor (L-dopa, 100mg). L-dopa will be combined with a dose of an Aromatic amino acid decarboxylase inhibitor (Benserazide) 25mg to multiplicate its bioavailability and with a dose of domperidone 10mg (peripheral antagonist of DA) to minimize the risk of side effects. |
Other: Dopamine precursor |
|
Active Comparator: D2 antagonist In the second condition, volunteers will receive a D2 antagonist (Sulpiride, 800mg) |
Other: antagoniste D2 |
|
Placebo Comparator: PLACEBO In the third condition, volunteers will receive a placebo (lactose) |
Other: PLACEBO |
| Ages Eligible for Study: | 18 Years to 45 Years |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Le Vinatier Hospital Center
Bron, France, 69678